Denmark warns against overtreatment with Ozempic
People with diabetes should try cheaper and milder treatments before getting Novo Nordisk’s Ozempic prescribed, says the Danish Health Authority.
by RITZAU, translated by kristoffer grønbæk
A division under the Danish Health Authority argues that too many people with type 2 diabetes are given Novo Nordisk’s treatment, Ozempic, before having tried other alternatives first.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Denmark warns of Novo Nordisk diabetes drug shortage
For subscribers
